La Dra. Martina Amiguet Comins comenta los resultados del estudio publicado en ESC Congress 2022.

1. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Pooled analysis from DELIVER and DAPA-HF trials
Presentación del ESC Congress 2022
DOI https://doi.org/10.1038/s41591-022-01971-4
Dapagliflozin Evaluation to improve
the LIVEs of patients with PReserved
Ejection Fraction Heart Failure
DELIVER
Dapagliflozin in Patients with
Heart Failure and Reduced
Ejection Fraction
DAPA-HF
+

2. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Pooled analysis from DELIVER and DAPA-HF trials
Presentación del ESC Congress 2022
DOI https://doi.org/10.1038/s41591-022-01971-4

3. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Pooled analysis from DELIVER and DAPA-HF trials
Presentación del ESC Congress 2022
DOI https://doi.org/10.1038/s41591-022-01971-4
Background Rationale
SGLT2i have shown benefit in CVD, HF irrespective of LVEF and CKD, regardless of diabetes status.
DAPA-HF and DELIVER were not individually powered to test de effect of dapagliflozin
on the components of the primary outcome and important secondary outcomes

4. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Pooled analysis from DELIVER and DAPA-HF trials
Presentación del ESC Congress 2022
DOI https://doi.org/10.1038/s41591-022-01971-4
Background Rationale Study population

5. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Pooled analysis from DELIVER and DAPA-HF trials
Presentación del ESC Congress 2022
DOI https://doi.org/10.1038/s41591-022-01971-4
Background Rationale Study population
Six EF categories are analyzed, with meaningful differences among them

6. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Pooled analysis from DELIVER and DAPA-HF trials
Presentación del ESC Congress 2022
DOI https://doi.org/10.1038/s41591-022-01971-4
Background Rationale Study population Methods
The following endpoints were studied in this pre-specified hierarchy to control alpha:
CV DEATH
All cause DEATH
Total (1st and repeated) HF hospitalisations
CV death/MI/stroke (MACE)
Composite CV death and 1st HF hospitalisation was examined to allow comparaison with EMPEROR trials

7. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Pooled analysis from DELIVER and DAPA-HF trials
Presentación del ESC Congress 2022
DOI https://doi.org/10.1038/s41591-022-01971-4
10%
14%
28%

8. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Pooled analysis from DELIVER and DAPA-HF trials
Presentación del ESC Congress 2022
DOI https://doi.org/10.1038/s41591-022-01971-4
Background Rationale Study population Methods Results

9. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Pooled analysis from DELIVER and DAPA-HF trials
Presentación del ESC Congress 2022
DOI https://doi.org/10.1038/s41591-022-01971-4
Background Rationale Study population Methods Results

10. Martina Amiguet Comins
Espacio reservado para
la imagen del ponente
Pooled analysis from DELIVER and DAPA-HF trials
Presentación del ESC Congress 2022
DOI https://doi.org/10.1038/s41591-022-01971-4
Background Rationale Study population Methods Results
Dapagliflozin showed consistent benefit across the spectrum of LVEF
Conclusions